Hybritech patent
Executive Summary
A federal appeals court Sept. 19 upheld a Hybritech patent covering a method of using monoclonal antibodies in immunometric assays for the detection and monitoring of physiologically significant conditions. The Hybritech patent, no. 4,376,110, had earlier been declared invalid in federal court in Northern California under a suit filed by Hybritech against Monoclonal Antibodies, Inc. The case has been remanded to the district court to determine now whether the Hybritech patent is being infringed by Monoclonal Antibodies' manufacture and sale of immunoassay test kits.